Gestational Trophoblastic Disease (FIGO 2021)
Gestational trophoblastic disease (GTD) is a rare condition that affects women during pregnancy. It is characterized by abnormal growth of cells in the uterus, specifically in the tissue that would normally develop into the placenta. This disease can have serious implications for both the mother and the developing fetus. In this article, we will the explore the latest information on GTD based on the FIGO 2021 guidelines.
Understanding Gestational Trophoblastic Disease: A Comprehensive Overview
Gestational trophoblastic disease (GTD) encompasses a group of conditions that arise from abnormal growth of placental cells during pregnancy. Although it is relatively rare, affecting approximately 1 in every 1,000 pregnancies, it is crucial to raise awareness about this condition to ensure early detection and appropriate management.
Types of GTD:
GTD is broadly categorized into two main types: hydatidiform mole and gestational trophoblastic neoplasia. Hydatidiform mole is further divided into complete and partial moles, while gestational trophoblastic neoplasia includes invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Each type presents unique characteristics and requires tailored treatment approaches.
Signs and Symptoms:
The signs and symptoms of GTD can vary depending on the type and stage of the disease. Common indications include abnormal vaginal bleeding, severe nausea and vomiting (hyperemesis gravidarum), enlarged uterus, and elevated levels of human chorionic gonadotropin (hCG) in the blood. However, it is important to note that these symptoms can also be associated with normal pregnancy, making accurate diagnosis challenging
